Basit öğe kaydını göster

dc.contributor.authorSönmez, Hafize Emine
dc.contributor.authorBatu, Ezgi Deniz
dc.contributor.authorÖzen, Seza
dc.date.accessioned2019-12-10T10:37:19Z
dc.date.available2019-12-10T10:37:19Z
dc.date.issued2016
dc.identifier.issn1178-7031
dc.identifier.urihttps://doi.org/10.2147/JIR.S91352
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803250/
dc.identifier.urihttp://hdl.handle.net/11655/14000
dc.description.abstractFamilial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disease, and it is characterized by recurrent attacks of fever and polyserositis. The disease is associated with mutations in the MEFV gene encoding pyrin, which causes exaggerated inflammatory response through uncontrolled production of interleukin 1. The major long-term complication of FMF is amyloidosis. Colchicine remains the principle therapy, and the aim of treatment is to prevent acute attacks and the consequences of chronic inflammation. With the evolution in the concepts about the etiopathogenesis and genetics of the disease, we have understood that FMF is more complicated than an ordinary autosomal recessive monogenic disorder. Recently, recommendation sets have been generated for interpretation of genetic testing and genetic diagnosis of FMF. Here, we have reviewed the current perspectives in FMF in light of recent recommendations.
dc.relation.isversionof10.2147/JIR.S91352
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleFamilial Mediterranean Fever: Current Perspectives
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalJournal of Inflammation Research
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları
dc.identifier.volume9
dc.identifier.startpage13
dc.identifier.endpage20
dc.description.indexPubMed
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster